You are now leaving Celsius Therapeutics to visit a third-party website, which is solely responsible for all content and privacy policies.
Chief Business Officer
Michael Boretti has nearly 15 years of experience in the biotechnology industry, including leadership roles encompassing business development, strategic planning, and program and alliance management. He brings to Celsius a strong track record of planning, negotiating and implementing strategic alliances across a wide range of collaboration structures. Prior to Celsius, Michael was vice president of business development at Epizyme, where he was responsible for the formation new partnerships, including key collaborations with Boehringer Ingelheim and Roche, while also overseeing management of numerous other strategic alliances. Previously, Michael worked in roles of increasing responsibility at AVEO Oncology, most recently serving as vice president, corporate development and alliance management, where he drove the formation of partnerships around many of AVEO’s clinical and discovery-stage programs, including significant transactions with Novartis, Janssen and Astellas. AVEO’s co-development/co-commercialization alliance with Astellas Pharmaceuticals was the recipient of the Scrip 2011 Licensing Deal of the Year Award. Prior to joining AVEO, Michael was a consultant in the life sciences practice at L.E.K. Consulting, a global strategic consulting firm.
Michael holds an undergraduate degree in engineering science from the University of Virginia and a Ph.D. in bioengineering from the University of Pennsylvania.